HLA class I-restricted MYD88 L265P-derived peptides as specific targets for lymphoma immunotherapy.
Nelde A, Walz JS, Kowalewski DJ, Schuster H, Wolz OO, Peper JK, Cardona Gloria Y, Langerak AW, Muggen AF, Claus R, Bonzheim I, Fend F, Salih HR, Kanz L, Rammensee HG, Stevanović S, Weber AN.
Nelde A, et al. Among authors: fend f.
Oncoimmunology. 2016 Dec 23;6(3):e1219825. doi: 10.1080/2162402X.2016.1219825. eCollection 2017.
Oncoimmunology. 2016.
PMID: 28405493
Free PMC article.